BioSpace News Archive

Kelyniam Global, a maker of custom cranial implants, announced results for its quarter ended June 30, 2022.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The term ‘substance abuse’ refers to a pattern of drug or substance usage that results in serious issues or distress.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Current research directions in the upper limb prosthetics market hover around improving the performance outcomes so that the devices meet the functional requirements in amputees.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The report details an exhaustive account of the global saliva collection devices market along with numerous associated factors.

The growth in the optical coherence tomography market has been growing rapidly because of a lot of factors.

The growth opportunities in the gynecological cancer drugs market are increasing at a significant speed owing to numerous factors.

Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced that it will release financial results for the first six months and second quarter of 2022, after U.S. markets close on Wednesday, August 31, 2022.

Positive topline results from the DESTINY-Breast02 phase 3 trial of ENHERTU® versus physician’s choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.

Amsel Medical Corporation announced receipt of award and signing of a contract for a non-dilutive AFWERX Tactical Funding Increase of $1.5 million augmenting its original $1M Phase II SBIR Grant.

Rockwell Medical, Inc., a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced its financial and operational results for the second quarter ended June 30, 2022.